Is biotech subprime pharma? Too much Phase II, not enough Phase III
This article was originally published in Scrip
With big pharma facing a fall in revenues associated with the patent expiries of key blockbuster drugs coupled with a drying of its own R&D pipelines, it may be surprising that more biotech asset accumulation deals are not consummated. Closer examination of the pipelines of the biotech industry throws some light on why deal making has remained at a subdued rate.